Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Show me how to use this page

Sangamo Therapeutics Inc. Stock

Price
Target price
€0.49

€0.49

1.790%
0.0087
1.790%
€2.79

€2.79

 
Buy 11 Sell 13
Buy 11
Sell 13
02.05.24 / Tradegate WKN: 936386 / Symbol: SGMO / Name: Sangamo Therapeutics / Stock / Biotechnology & Medical Research / Small Cap /
Latest predictions
27.04.24
-1.72%
sell
31.03.24
-16.10%
sell
€4.61
19.03.24
-37.07%
buy
€2.76
18.03.24
-36.88%
buy
21.02.24
-54.90%
buy
€0.000
19.02.24
-66.44%
sell
Show more
Your prediction
Pros and Cons of Sangamo Therapeutics Inc. in the next few years
Wizard

Sangamo Therapeutics Inc. Stock

Sangamo Therapeutics Inc. gained 1.790% today.
Based on 11 Buy predictions and 13 Sell predictions the sentiment towards Sangamo Therapeutics Inc. is rather balanced.
On the other hand, the target price of 2 € is above the current price of 0.49 € for Sangamo Therapeutics Inc., so the potential is actually 311.02%.
Our community identified positive and negative aspects for Sangamo Therapeutics Inc. stock for the coming years. 1 users see the criterium "Unique positioning" as a plus for the Sangamo Therapeutics Inc. stock. On the other hand our users think that "Worthwhile Investment for the next years" could be a problem in the future.
What does Sangamo Therapeutics do?

Pros and Cons of Sangamo Therapeutics Inc. in the next few years

Pros
?
B****
?
S********** s********
?
G***** c******* t* c**********
Cons
?
M***** P*******
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Your Opinion
Legal notice

Performance of Sangamo Therapeutics Inc. vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Sangamo Therapeutics Inc. 1.790% 3.576% -9.805% -60.790% -15.389% -95.032% -95.054%
Ardelyx Inc. 5.440% 7.123% -7.526% 58.693% 9.273% 3.541% -
Salarius Pharmaceuticals Inc. -2.830% -5.069% 5.641% -71.389% -25.766% -98.474% -99.994%
Brainstorm Cell 5.560% -26.131% -44.654% -86.685% 58.405% -87.328% -

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2023-04-15

Sangamo Therapeutics, a company in the Biotechnology & Medical Research industry with the US symbol SGMO, has displayed a mixed financial performance over the past few years. The company's financial statements show some strengths and areas of concern. A detailed analysis of Sangamo Therapeutics' financials reveals the following pros and cons:

*Pros: *

Revenue Growth: Sangamo Therapeutics has experienced revenue growth over the last three periods, demonstrating its ability to generate higher sales. This is a positive sign for the company as it shows market demand for its products and services.

Show more

Comments

Sangamo Therapeutics, Inc. (NASDAQ: SGMO) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Ratings data for SGMO provided by MarketBeat
Show more

StockNews.com 
0
Report Share
27.04.24 Sell -1.72%
Prediction Buy
Perf. (%) -37.07%
Target price 4.606
Change
Ends at 19.03.25

Sangamo Therapeutics, Inc. (NASDAQ: SGMO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock, up previously from $3.00.
Ratings data for SGMO provided by MarketBeat
Show more

HC Wainwright 
0
Report Share
19.03.24
Prediction Buy
Perf. (%) -36.88%
Target price 2.759
Change
Ends at 18.03.25

Sangamo Therapeutics, Inc. (NASDAQ: SGMO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $3.00 price target on the stock.
Ratings data for SGMO provided by MarketBeat
Show more

HC Wainwright 
0
Report Share
18.03.24
Show more
Not a member yet? Sign up for free!

News

Sangamo Therapeutics Announces First Quarter 2024 Conference Call and Webcast: https://mms.businesswire.com/media/20191101005100/en/736004/5/Sangamo_logoTM.jpg
Sangamo Therapeutics Announces First Quarter 2024 Conference Call and Webcast


Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the company has scheduled the release of its first quarter 2024 financial results after the market closes

BusinessWire_EN 
0 02.05.24
Sangamo Therapeutics to Present Neurology-Focused Pre-Clinical Data From Its Epigenetic Regulation, Capsid Delivery and Genome Engineering Platforms at the 27th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT): https://mms.businesswire.com/media/20191101005100/en/736004/5/Sangamo_logoTM.jpg
Sangamo Therapeutics to Present Neurology-Focused Pre-Clinical Data From Its Epigenetic Regulation, Capsid Delivery and Genome Engineering Platforms at the 27th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)


Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the American Society of Gene & Cell Therapy (ASGCT) has accepted 20 Sangamo abstracts for presentation at

BusinessWire_EN 
0 22.04.24
Sangamo Therapeutics Announces Pricing of $24.0 Million Registered Direct Offering: https://mms.businesswire.com/media/20191101005100/en/736004/5/Sangamo_logoTM.jpg
Sangamo Therapeutics Announces Pricing of $24.0 Million Registered Direct Offering


Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that it has entered into a securities purchase agreement with institutional investors, providing for the

BusinessWire_EN 
0 22.03.24